Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Consensus Price Target of $17.75 According to Brokerages

Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) have been given an average rating of “Hold” by the seven research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $17.75.

A number of brokerages have weighed in on TRDA. Roth Capital restated a “buy” rating and issued a $11.00 price objective on shares of Entrada Therapeutics in a report on Wednesday, August 12th. HC Wainwright reaffirmed a “neutral” rating on shares of Entrada Therapeutics in a research note on Monday, October 19th. Wall Street Zen raised shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. UBS Group reiterated a “neutral” rating on shares of Entrada Therapeutics in a research report on Monday, October 19th. Finally, Weiss Ratings downgraded shares of Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 16th.

Entrada Therapeutics Trading Down 6.8%

TRDA stock opened at $4.41 on Friday. Entrada Therapeutics has a 12-month low of $4.11 and a 12-month high of $16.45. The business’s 50-day moving average is $6.33 and its 200 day moving average is $7.67. The stock has a market cap of $171.71 million, a price-to-earnings ratio of -1.11 and a beta of -0.24.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $2.32 million. As a group, equities analysts forecast that Entrada Therapeutics will post -4.03 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Bioventures 2018 L.P. Mpm sold 192,500 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $7.41, for a total transaction of $1,426,425.00. Following the completion of the sale, the insider owned 3,913,952 shares of the company’s stock, valued at approximately $29,002,384.32. This represents a 4.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Ventures V. L.P. 5Am sold 114,756 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $6.93, for a total transaction of $795,259.08. Following the sale, the insider directly owned 2,848,310 shares of the company’s stock, valued at approximately $19,738,788.30. This represents a 3.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 946,961 shares of company stock worth $6,725,291. 9.49% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. State of Wyoming purchased a new stake in shares of Entrada Therapeutics in the second quarter valued at approximately $37,000. ADAR1 Capital Management LLC acquired a new stake in shares of Entrada Therapeutics in the second quarter valued at approximately $114,000. Deutsche Bank AG purchased a new position in Entrada Therapeutics during the second quarter worth approximately $195,000. Ieq Capital LLC purchased a new position in Entrada Therapeutics during the second quarter worth approximately $218,000. Finally, Odyssean LLC purchased a new position in Entrada Therapeutics during the second quarter worth approximately $230,000. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments.

Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.